The Pharmaceutical Benefits Advisory Committee (PBAC) has made several recommendations for drug listings on the Australian Pharmaceutical Benefits Scheme (PBS) after July 2023 meeting. Some highlights include:
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.